Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial

ObjectiveThis study aimed to evaluate the efficacy and safety of venetoclax in combination with hypomethylating agents and CAG (VEN-DCAG) regimens in patients with relapsed/refractory acute myeloid leukemia (R/R AML).MethodsThe treatment response was analyzed by retrospective methods in R/R AML pati...

Full description

Bibliographic Details
Main Authors: Yifan Liu, Yanfen Li, Ran Zhang, Zhangyu Yu, Yu Jing
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Immunology
Subjects:
venetoclax
hypomethylating agents
CAG regimen
relapsed/refractory
acute myeloid leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1269163/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1269163/full

Similar Items